Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Targeting drug tolerant persisters in colorectal cancer via anti-apoptosis inhibition
FY 2020-21
Summary
Targeting chemotherapy resistant cells in colorectal cancer Colorectal cancer (CRC) is the third highest cause of cancer-related deaths in North America, and chemotherapy resistance presents a major challenge to successful therapy. In some cases, tumour cells enter a slow-growth state to escape chemotherapy and resume rapid growth once chemotherapy is stopped. These cells are known as drug tolerant persisters (DTPs) and are emerging as key players in mediating chemotherapy resistance. Our previous work showed that these DTPs were maintained by autophagy, a process through which cells recycle damaged cellular components for survival. Inhibition of autophagy using a small molecule inhibitors modestly increased cell death (apoptosis) of DTPs. To identify additional methods by which DTPs survive chemotherapy, we conducted an unbiased drug screen which indicated that DTPs increase anti-apoptosis proteins to prevent cell death, which I confirmed experimentally. We hypothesize that combining inhibitors of autophagy with inhibitors of anti-apoptosis proteins will significantly enhance tumour cell death. To do this, I will treat patient derived CRC cell cultures with anti-apoptosis inhibitors (Venetoclax, Navitoclax, or AMG-176) to determine whether these drugs induce tumour cell death. These drugs will then be combined with an autophagy inhibitor to see if there is increased cell death. If so, this treatment regimen will be tested in CRC mouse models. This project will contribute to a better understanding of DTPs in chemoresistance and uncover new mechanisms to target DTPs. Using Venetoclax for CRC treatment is very promising as it is already approved by the FDA, offering safe and rapid introduction of a new treatment regimen to improve CRC patient outcomes.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449631
Name
Sharifi Lea
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting drug tolerant persisters in colorectal cancer via anti-apoptosis inhibition
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Apoptosis; Apoptosis; Autophagy; Chemotherapy Resistance; Colorectal Cancer; Cpt-11; Drug Tolerant Persisters; Drug Treatment; Patient-Derived Cell Culture
Abstract
Targeting chemotherapy resistant cells in colorectal cancer Colorectal cancer (CRC) is the third highest cause of cancer-related deaths in North America, and chemotherapy resistance presents a major challenge to successful therapy. In some cases, tumour cells enter a slow-growth state to escape chemotherapy and resume rapid growth once chemotherapy is stopped. These cells are known as drug tolerant persisters (DTPs) and are emerging as key players in mediating chemotherapy resistance. Our previous work showed that these DTPs were maintained by autophagy, a process through which cells recycle damaged cellular components for survival. Inhibition of autophagy using a small molecule inhibitors modestly increased cell death (apoptosis) of DTPs. To identify additional methods by which DTPs survive chemotherapy, we conducted an unbiased drug screen which indicated that DTPs increase anti-apoptosis proteins to prevent cell death, which I confirmed experimentally. We hypothesize that combining inhibitors of autophagy with inhibitors of anti-apoptosis proteins will significantly enhance tumour cell death. To do this, I will treat patient derived CRC cell cultures with anti-apoptosis inhibitors (Venetoclax, Navitoclax, or AMG-176) to determine whether these drugs induce tumour cell death. These drugs will then be combined with an autophagy inhibitor to see if there is increased cell death. If so, this treatment regimen will be tested in CRC mouse models. This project will contribute to a better understanding of DTPs in chemoresistance and uncover new mechanisms to target DTPs. Using Venetoclax for CRC treatment is very promising as it is already approved by the FDA, offering safe and rapid introduction of a new treatment regimen to improve CRC patient outcomes.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sharifi, Lea
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~